Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 27;11(9):791.
doi: 10.3390/v11090791.

Phylodynamics of Influenza A/H1N1pdm09 in India Reveals Circulation Patterns and Increased Selection for Clade 6b Residues and Other High Mortality Mutants

Affiliations

Phylodynamics of Influenza A/H1N1pdm09 in India Reveals Circulation Patterns and Increased Selection for Clade 6b Residues and Other High Mortality Mutants

Dillon C Adam et al. Viruses. .

Abstract

The clinical severity and observed case fatality ratio of influenza A/H1N1pdm09 in India, particularly in 2015 and 2017 far exceeds current global estimates. Reasons for these frequent and severe epidemic waves remain unclear. We used Bayesian phylodynamic methods to uncover possible genetic explanations for this, while also identifying the transmission dynamics of A/H1N1pdm09 between 2009 and 2017 to inform future public health interventions. We reveal a disproportionate selection at haemagglutinin residue positions associated with increased morbidity and mortality in India such as position 222 and clade 6B characteristic residues, relative to equivalent isolates circulating globally. We also identify for the first time, increased selection at position 186 as potentially explaining the severity of recent A/H1N1pdm09 epidemics in India. We reveal national routes of A/H1N1pdm09 transmission, identifying Maharashtra as the most important state for the spread throughout India, while quantifying climactic, ecological, and transport factors as drivers of within-country transmission. Together these results have important implications for future A/H1N1pdm09 surveillance and control within India, but also for epidemic and pandemic risk prediction around the world.

Keywords: India; Influenza; phylogenetics; public health.

PubMed Disclaimer

Conflict of interest statement

Author C.R.M. has sat on advisory boards for GlaxoSmithKline (GSK), Seqirus, Sanofi and Pfizer and has received funding or in-kind support for investigator-driven research from GSK, Seqirus, Sanofi, Wyeth, and Pfizer unrelated to this study. All other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
(a) Bayesian Skygrid estimation of effective viral population size (Ne) of A/H1N1pdm09 in India between 2009 and 2017. Here, we show the mean Ne and respective 95% Bayesian credible interval (BCI) plotted in blue. (b) Official A/H1N1pdm09 case and death counts (left axis) reported by the National Centre for Disease Control in Delhi (NCDC) [15,16]. Calculated yearly case fatality ratios (CFR) with corresponding percentages shown (right axis). The arrow in Figure 1a points to the inferred seasonal epidemic in 2013/14, in contrast to reported cases in Figure 1b.
Figure 2
Figure 2
Relative structural locations of A/H1N1pdm09 residues within the HA monomer under positive selection in India. Sites under selection are highlighted in red and numbered without signal peptide (H1 numbering). Letters in parentheses indicate sites located within the known antigenic domains of HA1. (RCSB PDB ID: 4LXV).
Figure 3
Figure 3
Phylogeography of definitive A/H1N1pdm09 transmission between S/UT in India since 2009. Paths between S/UT are coloured by inferred transmission time and directions indicated by adjacent arrows. All routes shown are characterised by definitive statistical support (Bayes factor (BF) > 100). Supported to very strongly supported routes (100 > BF > 3) are not shown but can be seen in Supplementary Table S8.

Similar articles

Cited by

References

    1. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine. 2010;28:4895–4902. doi: 10.1016/j.vaccine.2010.05.031. - DOI - PubMed
    1. Peiris J.S.M., Poon L.L.M., Guan Y. Emergence of a novel swine-origin influenza a virus (S-OIV) H1N1 virus in humans. J. Clin. Virol. 2009;45:169–173. doi: 10.1016/j.jcv.2009.06.006. - DOI - PMC - PubMed
    1. Webb S.A.R., Pettilä V., Seppelt I., Bellomo R., Bailey M., Cooper D.J., Cretikos M., Davies A.R., Finfer S., Harrigan P.W.J., et al. Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand. N. Engl. J. Med. 2009;361:1925–1934. - PubMed
    1. Mitchell R., Ogunremi T., Astrakianakis G., Bryce E., Gervais R., Gravel D., Johnston L., LeDuc S., Roth V., Taylor G., et al. Impact of the 2009 influenza A (H1N1) pandemic on Canadian health care workers: A survey on vaccination, illness, absenteeism, and personal protective equipment. Am. J. Infect. Control. 2012;40:611–616. doi: 10.1016/j.ajic.2012.01.011. - DOI - PubMed
    1. Wong J.Y., Kelly H., Ip D.K.M., Wu J.T., Leung G.M., Cowling B.J. Case fatality risk of influenza a (H1N1pdm09): A systematic review. Epidemiology. 2013;24:830–841. doi: 10.1097/EDE.0b013e3182a67448. - DOI - PMC - PubMed

Publication types

Substances